Nitric oxide to prevent bronchopulmonary dysplasia

December 2006
Archives of Disease in Childhood;Dec2006, Vol. 91 Issue 12, p1022
Academic Journal
The article focuses on a study that examines nitric oxide (NO) which is said to prevent bronchopulmonary dysplasia (BPD). There has beenanimal evidence that inhaled NO reduces lung inflammation, improves surfactant function, and promotes lung growth. With this, it might prevent BPD. Multicenter trials in preterm infants with respiratory failure have provided support for treatment with inhaled NO. Trials have found no evidence of harm and NO may prevent BPD, specifically among larger infants.


Related Articles

  • NO therapy holds great promise for tiniest preemies. Asch-Goodkin, Judith // Contemporary Pediatrics;Sep2006, Vol. 23 Issue 9, p17 

    The article focuses on the findings of multicenter clinical studies regarding the treatment with inhaled nitric oxide to prevent chronic lung disease in some very-low birth-weight premature infants. The studies involved infants treated at 37 medical centers which were born at less than 34 weeks'...

  • No more inhaled nitric oxide for premature infants?  // Contemporary OB/GYN;Sep2005, Vol. 50 Issue 9, p14 

    Discusses research being done on the treatment of premature infants with nitric oxide (NO). Reference to the studies of K. P. Van Meurs and colleagues and K. K. Mestan and colleagues published in 2005 issues of the "New England Journal of Medicine"; Rate of death or bronchopulmonary dysplasia;...

  • Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension. Rosati, Enrico; Butera, Gianfranco; Bossone, Eduardo; De Felice, Claudio; Latini, Giuseppe // European Journal of Pediatrics;Jul2007, Vol. 166 Issue 7, p737 

    This article presents a case study of inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH). PH is a common cardiovascular complication associated with increased morbidity and mortality in preterm infants with BPD....

  • Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. Ambalavanan, N.; Van Meurs, K. P.; Perritt, R.; Carlo, W. A.; Ehrenkranz, R. A.; Stevenson, D. K.; Lemons, J. A.; Poole, W. K.; Higgins, R. D. // Journal of Perinatology;Jun2008, Vol. 28 Issue 6, p420 

    Objectives:To identify the variables that predict death/physiologic bronchopulmonary dysplasia (BPD) in preterm infants with severe respiratory failure.Study Design:The study was a secondary analysis of data from the NICHD Neonatal Research Network trial of inhaled nitric oxide (iNO) in preterm...

  • Inhaled NO for Preterm Infants – Getting to Yes? Stark, Ann R. // New England Journal of Medicine;7/27/2006, Vol. 355 Issue 4, p404 

    The author reflects on the advantages of inhaled nitric oxide (NO) among preterm infants. Lung inflammation linked with mechanical injury may contribute to bronchopulmonary dysplasia among preterm infants. Reports showed that inhaled NO improved oxygenation in preterm infants with severe...

  • Clara cell secretory protein and bronchopulmonary dysplasia in prematurely born infants. Greenough, Anne // European Journal of Pediatrics;Nov2008, Vol. 167 Issue 11, p1347 

    An introduction to articles published within the issue is presented, including on the observation of elevated Clara cell protein 16 (CC16) concentrations found in prematurely born infants with lung injury and another on cord blood concentrations of CC16 found in infants who developed...

  • Pulmonary Dendritic Cells in Lungs of Preterm Infants: Neglected Participants in Bronchopulmonary Dysplasia? DE PAEPE, MONIQUE E.; HANLEY, L. COREY; LACOURSE, ZACHARIE; PASQUARIELLO, TERESE; MAO, QUANFU // Pediatric & Developmental Pathology;Jan/Feb2011, Vol. 14 Issue 1, p20 

    Preterm infants are at risk for bronchopulmonary dysplasia (BPD), a chronic lung disease characterized by disrupted alveolar remodeling and microvascular dysangiogenesis. The pathogenesis of BPD is multifactorial, with contributions from antenatal and/or postnatal infection and inflammation. The...

  • Validation of ICD-9 diagnostic codes for bronchopulmonary dysplasia in Quebec's provincial health care databases. Landry, J. S.; Croitoru, D.; Menzies, D. // Chronic Diseases & Injuries in Canada;Dec2012, Vol. 33 Issue 1, p47 

    Introduction: Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease caused by neonatal lung injury. The aim of this study was to validate the use of ICD-9 diagnostic codes for BPD in administrative databases to allow for their use in health care utilization analyses. Methods: The...

  • Using Cell-Based Strategies to Break the Link between Bronchopulmonary Dysplasia and the Development of Chronic Lung Disease in Later Life. O'Reilly, Megan; Thébaud, Bernard // Pulmonary Medicine;2013, p1 

    Bronchopulmonary dysplasia (BPD) is the chronic lung disease of prematurity that affects very preterm infants. Although advances in perinatal care have changed the course of lung injury and enabled the survival of infants born as early as 23-24 weeks of gestation, BPD still remains a common...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics